Cancer treatment company plans for public offeringJuly 25, 2019PetCure Oncology has engaged Boustead Securities for a Regulation D 506(c) offering.
SPONSORED CONTENTProtect your patients from the start.Simparica Trio (sarolaner, moxidectin, and pyrantel chewable tablets) is the first monthly preventative of its kind. Combining three ingredients for month-long protection. + Learn more
Ohio State opens expanded veterinary oncology suiteMay 29, 2019Ohio State University's Veterinary Medical Center has opened the Blue Buffalo Foundation Integrated Oncology Suite, allowing practitioners to comprehensively and holistically treat pets with cancer. Blue Buffalo granted the school $650,000 to renovate the suite. "Blue Buffalo was founded on a mission to help cure a disease causing 50 percent of health-related pet deaths," says the company's vice president, David Petrie. "In supporting the renovation of the integrated oncology space, we are able to support veterinary medicine so dogs and cats facing cancer can receive a cohesive team approach, resulting in better health outcomes." The suite's team comprises veterinarians with specialties in medical, surgical, and radiation oncology. Clinical trials also are a big part of the integrated oncology service and are managed by the Blue Buffalo Veterinary Clinical Trials Office. The company's funding will help support animals enrolled in a study. "Our partnership with Blue Buffalo has made it possible to provide studies that test new diagnostics and treatments across a wide spectrum of pet health, including cancer, renal failure, heart disease, and arthritis," says Cheryl London, DVM, PhD, clinical trials office director and professor of veterinary biosciences. "Clinical trials in veterinary medicine are critical for identifying new approaches to …
The race to develop immunotherapies for canine lymphoma and osteosarcomaJanuary 2, 2019There are many reasons why development of immunotherapies in dogs has been slow. Although cancer, and in particular lymphoma and osteosarcoma, is frequent in dogs, just one percent of owners have pet insurance; those who don’t are willing to spend only a limited amount of money to treat their dog, especially when initial treatment results are not as dramatic as in humans.
Cancer tech's futureNovember 22, 2018Veterinary oncology imaging has evolved greatly over the past decade, allowing for earlier detection, improved treatment, and more successful outcomes. Veterinary Practice News reached out to three prominent veterinary oncology centers around the U.S. to discuss imaging equipment, promising research, and what the future holds in this important field.
V Foundation announces grant-making program for canine oncology researchNovember 14, 2018The V Foundation has announced a grant-making program to accelerate research in the field of comparative oncology, enabling researchers from human and veterinary medicine to explore new cancer therapies.
Michigan specialty veterinary care center seeks dogs for cancer studySeptember 19, 2017 Oakland Veterinary Referral Services (OVRS) specialty veterinary care center is conducting a nationwide study on dogs with canine splenic hemangiosarcoma (HSA) and the benefits of using traditional Chinese herbal medicine (TCHM) as treatment to significantly extend life expectancy. Erin Bannink, DVM, DACVIM, VCHM, CVA, is leading the study, according to Lucy Henney, DVM, DACVS, owner of Bloomfield Hills, Mich.-based OVRS. Most dogs diagnosed with HSA are treated by removal of the spleen after the tumor has ruptured and bled, causing life-threatening blood loss; most dogs living only two months after surgery due to the spread of cancer to other organs, according to Dr. Bannink. Because of HSA's aggressive nature, chemotherapy is usually recommended after surgery in the hope of prolonging life, but it only modestly prolongs survival, and most dogs still die of cancer spread within three to four months of diagnosis, she said. "The purpose of this study is to determine if treatment with a specific herbal therapy regimen is helpful in prolonging survival time after surgery in dogs with HSA and no evidence of cancer spread," said Bannink. "We hypothesize that dogs treated with this standardized protocol after splenectomy will have …
